Shorter Antibiotic Regimens Show Promise in Preventing Tuberculosis
A new study reveals that one- and three-month courses of antibiotics are both safe and effective in preventing active tuberculosis (TB), offering a potential breakthrough in global efforts to combat the disease. Published February 10th in PLOS Medicine, the research suggests a significant shift is possible from the traditionally recommended six-to-nine-month treatment regimens.
For decades, the World Health Organization (WHO) has advised lengthy antibiotic courses to prevent TB infection from developing after exposure. However, adherence to these extended treatments has consistently been a major challenge. This new evidence demonstrates that shorter durations – one month or three months – can be equally effective, potentially increasing treatment completion rates and ultimately reducing TB infections worldwide.
The clinical trial, conducted in Brazil, involved 500 participants who had been exposed to TB but were not living with HIV. Researchers randomly assigned participants to either a one-month daily regimen of isoniazid and rifapentine, or a three-month weekly regimen of the same drugs. Remarkably, both groups exhibited high rates of completion: 89.6% for the one-month course and 84.1% for the three-month course. Importantly, adverse reactions were reported as mild to moderate and occurred at similar rates in both groups.
“Both regimens were deemed successful and neither proved superior to the other,” according to the study findings. This parity is crucial, as it provides clinicians and public health officials with options tailored to individual patient needs and circumstances.
The challenge of lengthy treatments has long hindered efforts to expand preventive therapy for TB. A senior official stated, “Prevention of tuberculosis in people at the greatest risk is essential for global control of the disease, and shorter preventive treatment regimens will be instrumental in catalyzing uptake in high-burden countries.” The study’s findings offer compelling evidence that a one-month course is safe for all patients, regardless of HIV status, empowering informed decision-making.
Experts are optimistic that the success of these shorter treatments, coupled with the increasing availability of affordable, generic drug formulations suitable for at-home administration, will dramatically increase access to preventive care. One analyst noted, “Tuberculosis preventive treatment regimens have now been shortened from 6-9 months of daily medication to 1 month of daily treatment or 12 once-weekly doses, a transformational advance.”
Coauthor Betina Durovni emphasized the potential impact on high-burden countries, stating, “The high rates of treatment completion and excellent safety profile of the short-course regimens will help Brazil and other high-burden countries achieve TB control by facilitating widespread uptake of TB preventive treatment.”
Marcelo Cordeiro-Santos, another coauthor, added, “Preventing TB with short courses of well-tolerated medicines ensures that millions more people around the world can be protected from the devastating consequences of TB disease.”
The research team, led by Richard Chaisson of the Johns Hopkins School of Medicine, published their findings in the open-access journal PLOS Medicine. The study is available online at https://doi.org/10.1371/journal.pmed.1004758.
